Nuvalent climbs as Guardant diagnostic partnership and ASCO catalyst focus returns
NUVL•Nuvalent shares are higher after a newly announced multi-year collaboration with Guardant Health to develop companion diagnostics and support potential commercialization of Nuvalent’s targeted cancer therapies. Investors are also positioning ahead of Nuvalent’s upcoming ASCO 2026 oral presentation of pivotal ALKOVE-1 neladalkib data (May 29–June 2, 2026) and the company’s Q1 results expected May 7, 2026.
1) What’s moving the stock
Nuvalent (NUVL) is trading higher as investors react to fresh partnership news and a near-term catalyst calendar. The latest headline is a multi-year strategic collaboration with Guardant Health to develop companion diagnostics and support clinical development and potential commercialization using Guardant’s Infinity platform, a development that can reduce friction around biomarker testing and launch-readiness for targeted oncology drugs. (investors.guardanthealth.com)
